|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2020-03-25 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2018-06-27 |
/ Unknown status临床1/2期IIT A Phase IB/II, Single Arm, Multi-center Study of Nivolumab in Combination With Eribulin in HER2 Negative Metastatic Breast Cancer Patients
Cancer therapeutics such as chemotherapy may modulate tumor/immune-system interactions in favor of the immune system. Chemotherapy can result in tumor cell death with a resultant increase in tumor antigen delivery to antigen-presenting cells. Therefore, combining immunotherapy (Nivolumab) with chemotherapy (Eribulin) is a promising anti-cancer strategy.
100 项与 Ono Pharma Korea Co., Ltd. 相关的临床结果
0 项与 Ono Pharma Korea Co., Ltd. 相关的专利(医药)
100 项与 Ono Pharma Korea Co., Ltd. 相关的药物交易
100 项与 Ono Pharma Korea Co., Ltd. 相关的转化医学